Arete Wealth Advisors’s Pacific Biosciences PACB Stock Holding History

Arete Wealth Advisors’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-32,616	Closed	-$58K	–	785
2024 Q4	$58K	Sell	32,616 -33,556	-51%	-$65.5K	﹤0.01%	729
2024 Q3	$114K	Sell	66,172 -16,748	-20%	-$27.5K	0.01%	671
2024 Q2	$110K	Buy	82,920 +26,052	+46%	+$52.6K	0.01%	687
2024 Q1	$213K	Buy	56,868 +39,757	+232%	+$233K	0.02%	373
2023 Q4	$168K	Buy	17,111 +4,664	+37%	+$38.1K	0.01%	689
2023 Q3	$104K	Sell	12,447 -419	-3%	-$4.79K	0.02%	467
2023 Q2	$171K	Sell	12,866 -834	-6%	-$10.1K	0.02%	608
2023 Q1	$159K	Buy	+13,700	New	+$136K	0.01%	588
2022 Q4	–	Sell	-15,042	Closed	-$87K	–	687
2022 Q3	$87K	Buy	15,042 +1,366	+10%	+$7.84K	0.01%	542
2022 Q2	$60K	Buy	+13,676	New	+$83.1K	0.01%	445

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arete Wealth Advisors's PACB Position: Q1 2025 in Review

Arete Wealth Advisors sold out of Pacific Biosciences (PACB) in Q1 2025, closing a stake of 32,616 shares — an estimated $58K sold.

Arete Wealth Advisors first reported a position in PACB in Q2 2022 and held it in 10 quarters. The position peaked at $213K in Q1 2024. 225 funds tracked by Wall St. Rank hold PACB as of Q1 2025.

Arete Wealth Advisors reported no remaining Pacific Biosciences position as of Q1 2025 after selling out during the quarter.
Arete Wealth Advisors sold 32,616 Pacific Biosciences shares in Q1 2025, an estimated $58K.
Arete Wealth Advisors first reported a position in Pacific Biosciences in Q2 2022 and held it in 10 quarters.
Arete Wealth Advisors's Pacific Biosciences position peaked at $213K in Q1 2024.
225 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2025.

Based on Arete Wealth Advisors's 13F filing for Q1 2025, filed 16 May 2025.